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Abstract
Background: Hepatic lipase (HL), an enzyme present in the hepatic sinusoids, is responsible for the lipolysis of
lipoproteins. Human HL contains four polymorphic sites: G-250A, T-710C, A-763G, and C-514T single-nucleotide
polymorphism (SNPs). The last polymorphism is the focus of the current study. The genotypes associated with the C-
514T polymorphism are CC (normal homozygous - W), CT (heterozygous - H), and TT (minor-allele homozygous - M).
HL activity is significantly impaired in individuals of the TT and CT genotypes. A total of 58 post-menopausal women
were studied. The subjects were hysterectomized women receiving hormone replacement therapy consisting of
0.625 mg of conjugated equine estrogen once a day. The inclusion criteria were menopause of up to three years and
normal blood tests, radiographs, cervical-vaginal cytology, and densitometry. DNA was extracted from the buccal and
blood cells of all 58 patients using a commercially available kit (GFX® - Amersham-Pharmacia, USA).
Results: Statistically significant reductions in triglycerides (t = 2.16; n = 58; p = 0.03) but not in total cholesterol (t
= 0.14; n = 58; p = 0.89) were found after treatment. This group of good responders were carriers of the T allele;
the CT and TT genotypes were present significantly more frequently than in the group of non-responders (p =
0.02 or p = 0.07, respectively). However, no significant difference in HDL-C (t = 0.94; n = 58; p = 0.35) or LDL-C (t =
-0.83; n = 58; p = 0.41) was found in these patients.
Conclusions: The variation in lipid profile associated with the C-514T polymorphism is significant, and the T allele
is associated with the best response to ERT.
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Background
Hepatic lipase (HL), an enzyme present in the hepatic
sinusoids, is responsible for the lipolysis of lipoproteins.
Although also expressed in other tissues, over 95% per-
cent of the total HL activity is found in the liver [1]. As
a key enzyme in lipoprotein metabolism, HL hydrolyzes
triglycerides (TG), intermediate-density lipoprotein
(IDL-C), high-density lipoprotein (HDL-C), and the sur-
face phospholipids and core TG of small very-low-den-
sity lipoprotein (VLDL-C) remnants. HL also aids in the
binding of lipoproteins to cellular receptors. In vitro
studies have demonstrated that HL facilitates the bind-
ing and entrance of chylomicrons, chylomicron rem-
nants, VLDL-cholesterol (VLDL-C), LDL-C [2,3] and
HDL cholesterol (HDL-C) [4-6] into a number of differ-
ent cell types. Fertile females have lower HL activity
than males [7,8].
Patients with HL deficiency often present with
hypercholesterolemia, hypertriglyceridemia and
increased levels of VLDL-C, remnant chylomicrons,
IDL-C, TG-rich LDL-C, and HDL-C [9-11]. However,
because not all patients with HL deficiency show these
metabolic changes, the condition is sometimes confused
with other genetic disorders [12].
The human HL gene, a 60 kb gene with a 1.6 kb exon,
is present on chromosome 15 [13,14]. The gene
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possesses four known polymorphic sites, and these four
sites are in complete linkage disequilibrium. The most
common polymorphisms are G-250A, T-710C, A-763G
and C-514T [7], and the most common haplotypes are
GTAC and ACGT. Because the C-514T polymorphism
occurs in the promoter region of the HL gene, it has
been suggested that this polymorphism may influence
the metabolic activity of the enzyme [15-17] but not
influence transcription [18]. Some authors have found
that the polymorphisms do not cause phenotypic
changes in females, although they have noted a HDL-C
difference in men [18,19]. Because HL activity may also
be controlled by circulating estrogen [16], it is likely
that further studies of the HL gene polymorphisms will
provide additional genetic information that may be use-
ful in developing more successful hormone replacement
therapies [20].
A meta-analysis of 24,000 cases has demonstrated that
HL activity is significantly lower in individuals with the
TT and CT genotypes for the C-514T polymorphism
than in individuals with the CC genotype [20]. Despite
its association with high HDL cholesterol, the presence
of the T allele results in a slightly increased risk of
atherosclerosis [7]. Human and animal studies have
found both atherogenic and anti-atherogenic activities
for the enzyme [21]. While low HL activity is associated
with a greater risk of arterial coronary disease (ACD)
[22], it is not directly responsible for this disorder [23].
Although there seems to be an inverse relationship
between HL level and atherosclerotic disease, a consen-
sus is lacking on this point; some studies have found
increased HL in patients with ACD [24]. In humans,
increased HL is associated with small, dense LDL-C par-
ticles and with lower levels of antiatherogenic large
HDL-C particles [24,25]. However, studies using animal
models have not confirmed this relationship, which sug-
gests that other factors may contribute to the develop-
ment of ACD. Because HL hydrolyzes phospholipids
and triglycerides and releases Fatty Acids (FA) from
phospholipids and triglycerides [26], increased HL
expression may cause more cholesterol to enter cells
and sub-endothelial LDL-C deposits, thus promoting
phagocytosis by macrophages and increasing the risk of
atherosclerotic lesions. As has been mentioned, HL can
have both pro- and anti-atherogenic effects. As an enzy-
matic or binding protein, it can change the level, com-
position or metabolism of lipoproteins in ways that can
either increase or decrease atherogenesis. In the pre-
sence of hypertriglyceridemia and increased LDL-C,
high HL activity (the formation of small, dense LDL-C)
has a pro-atherogenic effect. However, low levels of
LDL-C and high levels of HL may be due to the anti-
atherogenic effect of increased VLDL-C remnants and
IDL-C catabolism [27-29]. The pro- and anti-
atherogenic effects of HL may be mediated by the for-
mation of increased levels of small dense LDL-C in the
presence of hypertriglyceridemia and by the increased
catabolism of VLDL-C remnants and IDL-C, respec-
tively. A number of researchers believe that HL plays an
important role in the reverse transport of cholesterol
and that its role in this process may be the primary
mechanism responsible for the development of athero-
sclerotic disease [30-34]. There is still great controversy
in the literature regarding the pro- and anti-atherogenic
roles of HL [32].
Findings that suggest that high HL is responsible for
increased atherogenic potential include smaller LDL-C
particle size with increased HL activity, enzyme activity
that is inversely proportional to HDL-C level, greater
activity in males than in fertile females, and a positive
correlation of HL level with insulin resistance and/or
abdominal fat. Two findings that support an anti-athero-
genic role for the enzyme include its reverse cholesterol
transport activity and its role in TG clearing after meals
[35]. Environmental factors must also be taken into
account. There may be a strong interaction effect of HL
polymorphisms and the amount and type of dietary fat
on HDL-C level [36]. Body mass index (BMI), or adipos-
ity, also appears to affect HL activity, and this effect is
additive with the effects of the genetic polymorphisms
that have been analyzed [37]. There is also evidence that
HL activity is specifically related to the amount of intra-
abdominal fat [17,38].
A number of recent studies have failed to support the
efficacy of hormone replacement therapy [39-42]. The
Heart and Estrogen/Progestin Replacement Study
(HERS) conducted by Hulley in 1998 did not recom-
mend the use of HRT for the secondary prevention of
arterial coronary disease (ACD); however, due to good
ACD outcomes in women taking HRT for several years,
HRT continues to be used [39]. A recent study has
found that taking estrogen for a mean of 5.9 years was
not associated with any change in a woman’s ACD risk
[43]. Other studies have suggested that hormone repla-
cement therapy may cause pro-thrombotic susceptibility
in women with prior atherosclerosis [44].
Estrogen increases plasma levels of apolipoprotein A-1
(ApoA-1) and HDL-C, possibly by increasing ApoA-1
expression in the liver, and it modulates the expression
of proteins involved in HDL-C metabolism. Thus, we
can expect a high degree of inter-individual variability in
HRT response [45]. In rats, estrogen also seems to be
associated with the modulation of HL gene expression,
and raising HL level decreases HDL-C level [15]. The
mechanism by which estrogen reduces LDL-C and
increases HDL-C is different from the mechanism of
lipid-lowering drugs. This difference may explain why
HRT is not effective in preventing the progression of
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coronary heart disease in postmenopausal women
[46,47]. HL activity is susceptible to variations in endo-
genous sexual steroids. Estrogenic steroids suppress HL
activity, while androgenic steroids increase it [8,48]. The
effect of the C514T polymorphism on HL activity is
independent of androgen action [49].
The current study was motivated by the controversy
regarding the pro- and anti-atherosclerotic effects of HL
in women undergoing estrogen replacement therapy.
The objective of the study was to optimize hormone
replacement therapy by establishing the genetic patterns
associated with better responses to such treatment.
Results
Comparative analysis before and after treatment
The results are presented as the mean and standard
deviation of the variables (Table 1). Table 1 shows the
influence of estrogen replacement treatment on the
group as a whole. The values for cholesterol, HDL-C,
LDL-C, and triglycerides were analyzed independently of
genotype for the both pre- and post-treatment
conditions.
All of the genotypes were in Hardy-Weinberg equili-
brium (Table 2).
Comparative analysis of different genotypes before and
after treatment
To evaluate whether the baseline values of any of the
variables were influenced by genotype, Table 3 presents
the lipid profiles by genotype (major-allele homozygote,
heterozygote, and minor-allele homozygote).
To further study this potential influence, Table 4 com-
pares the means of the variables by genotype (shows the
results of testing). For this purpose, we used an
ANOVA model and compared the means by group.
We also analyzed the lipid levels before and after ERT;
these results are shown according to genotype in Table
5. In this analysis, we studied the influence of the treat-
ment on lipid levels. Table 6 shows the influence of the
T allele on the lipid profile and response to estrogen
treatment.
No statistically significant differences in total choles-
terol, HDL-C, or LDL-C were found after re-grouping
the genotypes into CT and TT (Table 6). Table 6 shows
the influence the T allele on the lipid profile and estro-
gen treatment.
Table 7 summarizes the data and shows the correla-
tions between the C and T alleles and the baseline lipid
values. An ANOVA model was used to compare the
mean lipoprotein levels in the patients with C and T
alleles.
Table 8 shows the influence of the C and T alleles on
the lipoprotein levels of the patients receiving hormone
replacement with estrogen. A multivariate ANOVA
model was used to compare the means of the patients
Table 1 Comparative analysis of the variables before and
after treatment, independent of genotype
Groups N Mean (mg/dL) Standard deviation t p
TotalChol 58 210.31 45.47 0.14 0.89
TotalChol2 58 209.41 43.19
HDL-C 58 58.95 13.45 0.94 0.35
HDL-C2 58 57.76 14.44
LDL-C 58 120.052 38.71 -0.83 0.41
LDL-C2 58 125.52 38.08
TG 58 138.07 65.40 2.16 0.03
TG2 58 122.07 66.50
TotalChol: total pre-treatment cholesterol; HDL-C: pre-treatment high-density
lipoprotein cholesterol; LDL-C: pre-treatment low-density lipoprotein
cholesterol; TG: pre-treatment triglycerides; TotalChol2: total post-treatment
cholesterol; HDL-C2: post-treatment high-density lipoprotein cholesterol; LDL-
C2: post-treatment low-density lipoprotein cholesterol; TG2: post-treatment
triglycerides.
Table 2 Numbers of expected and observed genotypes
according to Hardy-Weinberg equilibrium
CC (N) CT (N) TT (N) Chi-Square p*
Observed 15 29 14 0.000005 0.998
Expected 15.00 28.99 14.00
CC (major-allele homozygote); CT (heterozygote); TT (minor-allele
homozygote)
*p= 0,998
Table 3 Influence of genotype on baseline lipid levels
Genotype Variable N Mean Standard Deviation t-test p
CC TotalChol 15 216.27 47.36 0.15 0.89
CT TotalChol 29 205.42 44.03 0.08 0.94
TT TotalChol 14 214.07 48.65 0.03 0.98
CC HDL-C 15 57.87 12.56 1.31 0.21
CT HDL-C 29 57.17 12.18 0.21 0.84
TT HDL-C 14 63.78 16.44 0.36 0.72
CC LDL-C 15 134.40 42.83 -0.09 0.93
CT LDL-C 29 118.21 31.19 -0.14 0.89
TT LDL-C 14 108.50 45.96 -1.26 0.23
CC TG 15 132.60 45.50 1.07 0.30
CT TG 29 136.41 70.19 1.20 0.24
TT TG 14 147.36 76.01 1.71 0.11
TotalChol: total pre-treatment cholesterol; HDL-C: pre-treatment high-density
lipoprotein cholesterol; LDL-C: pre-treatment low-density lipoprotein
cholesterol; TG: pre-treatment triglycerides.
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with the C and T alleles. We then compared the lipo-
protein changes in response to the treatment, according
to genotype.
Discussion
A statistically significant difference in triglyceride level
was observed after ERT compared to baseline (Table 1).
To examine the efficacy of ERT, we did not differentiate
the subjects by genotype. No statistically significant dif-
ferences in lipoprotein levels were observed. The p
values for lipoprotein levels before and after treatment
were p = 0.89 and p = 0.35 for HDL-C and LDL-C,
respectively; in other words, HDL-C and LDL-C levels
did not change significantly after treatment. These find-
ings are probably related to the fact that the major sub-
strates of HL are TG and HDL-C rather than LDL-C
[17,26,27].
No statistically significant differences in the baseline
level of total cholesterol, HDL-C, LDL-C, or triglycerides
were observed among patients of different genotypes
(Tables 3 and 4). This finding is interesting because the
current literature suggests that polymorphisms can
directly influence HL activity, as revealed by differences
in lipid levels [48]. Recent results are consistent with
our findings regarding total cholesterol [18]. Our find-
ings were obtained using an ANOVA model that
Table 4 An ANOVA model comparing the mean baseline
lipid levels by genotype (major-allele homozygote,
heterozygote, and minor-allele homozygote)
ANOVA
Sum of
squares
df Mean
square
F Sig
TotalChol Between
Groups
1425.517 2 712.759 0.337 0.716
Within
Groups
116446.9 55 2117.216
Total 117872.4 57
HDL-C Between
Groups
436.616 2 218.308 1.216 0.304
Within
Groups
9874.228 55 179.531
Total 10310.845 57
LDL-C Between
Groups
5054.986 2 2,527.493 1.73 0.187
Within
Groups
80373.859 55 1461.343
Total 85428.845 57
TG Between
Groups
1735.875 2 867.938 0.197 0.822
Within
Groups
242037.8 55 4400.688
Total 243773.7 57
Table 5 Results of the paired-samples t-tests (before and
after treatment) according to genotype
Genotype Variable
(mg/dL)
N Mean Standard Deviation t-test p
CC TotalChol 15 216.27 47.36 0.15 0.89
TotalChol 2 15 214.60 39.09
CT TotalChol 29 205.41 44.03 0.08 0.94
TotalChol 2 29 204.66 39.76
TT TotalChol 14 214.07 48.65 0.03 0.98
TotalChol 2 14 213.71 55.03
CC HDL-C 15 57.87 12.56 1.31 0.21
HDL-C 2 15 54.87 15.47
CT HDL-C 29 57.17 12.18 0.21 0.84
HDL-C 2 29 56.76 13.38
TT HDL-C 14 63.79 16.44 0.36 0.72
HDL-C 2 14 62.93 15.16
CC LDL-C 15 134.40 42.83 -0.09 0.93
LDL-C2 15 135.40 34.27
CT LDL-C 29 118.21 31.19 -0.14 0.89
LDL-C2 29 19.62 38.01
TT LDL-C 14 108.50 45.96 -1.26 0.23
LDL-C2 14 127.14 42.28
CC TG 15 132.60 45.50 1.07 0.30
TG2 15 121.13 44.02
CT TG 29 136.41 70.19 1.20 0.24
TG2 29 121.83 73.78
TT TG 14 147.36 76.01 1.71 0.11
TG2 14 123.57 74.68
TotalChol: total pre-treatment cholesterol; HDL-C: pre-treatment high-density
lipoprotein cholesterol; LDL-C: pre-treatment low-density lipoprotein
cholesterol; TG: pre-treatment triglycerides; TotalChol2: total post-treatment
cholesterol; HDL-C2: post-treatment high-density lipoprotein cholesterol; LDL-
C2: post-treatment low-density lipoprotein cholesterol; TG2: post-treatment
triglycerides; CC: homozygous major-allele genotype; CT: heterozygous
genotype; TT: homozygous minor-allele genotype.
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compared the baseline means of the three different
groups (CC, CT and TT). The T allele was associated
with higher HDL-C in those individuals with a higher
proportion of fat in their diets. No significant differences
were observed among CC and CT individuals [36].
Because the patients in this study did not follow a speci-
fic diet, we believe that potential differences may have
been overshadowed by the variation in the patients’ diet-
ary habits. This factor may account for the published
data showing associations of the 514C > T polymorph-
ism with measures of HDL-C metabolism, depending on
the amount and type of fat consumed [36].
When the three genotypes were analyzed separately,
no significant changes in the triglycerides following ERT
Table 6 Paired-samples t-tests (before and after treatment) for the CT and TT genotypes
(mg/dL) Paired differences t df Sig (2-tailed)
Mean SD Mean Standard Error 95% Confidence interval
Lower Upper
Pair 1 TotalChol -TotalChol2 0.62791 50.96685 7.77237 -15.05738 16.31319 0.081 42 0.936
Pair 2 HDL-C - HDL-C-C2 0.55814 9.9506 1.51745 -2.5042 3.62048 0.368 42 0.715
Pair 3 LDL-C - LDL-C2 7.02326 53.53614 8.16419 -23.49925 9.45274 -0.86 42 0.395
HDL: pre-treatment high-density lipoprotein; LDL: pre-treatment low-density lipoprotein; VLDL: pre-treatment very-low-density lipoprotein; HDL2: post-treatment
high-density lipoprotein; LDL2: post-treatment low-density lipoprotein
Table 7 An ANOVA model comparing the baseline means
of the lipid variables between the C and T alleles
ANOVA
Sum of
squares
df Mean
square
F Sig
TotalChol Between
Groups
46.432 1 46.432 0.022 0.881
Within
Groups
235698.4 114 2067.53
Total 235744.8 115
HDL-C Between
Groups
243.083 1 243.083 1.36 0.246
Within
Groups
20378.607 114 178.76
Total 20621.69 115
LDL-C Between
Groups
4901.112 1 4901.112 3.367 0.069
Within
Groups
165956.6 114 1455.759
Total 170857.7 115
TG Between
Groups
1551.263 1 1551.263 0.364 0.548
Within
Groups
485996.2 114 4263.124
Total 487547.4 115
Table 8 Results of the paired-samples t-tests for
lipoproteins before and after treatment, by allele
Allele Variable
mg/dL
N Mean SD t-test p
C TotalChol 59 210.93 45.26 0.20 0.85
TotalChol2 59 209.71 39.06
T TotalChol 57 209.67 45.68 0.08 0.93
TotalChol2 57 209.11 47.08
C HDL-C 59 57.53 12.16 1.37 0.18
HDL-C2 59 55.80 14.24
T HDL-C 57 60.42 14.52 0.50 0.62
HDL-C2 57 59.79 14.35
C LDL-C 59 126.44 37.70 -0.20 0.84
LDL-C2 59 127.44 36.44
T LDL-C 57 113.44 38.62 -1.39 0.17
LDL-C2 57 123.32 39.58
C TG 59 134.47 58.15 1.85 0.07
TG2 59 121.47 59.69
T TG 57 141.79 71.95 2.46 0.02
TG2 57 122.68 72.88
TotalChol: total pre-treatment cholesterol; HDL-C: pre-treatment high-density
lipoprotein cholesterol; LDL-C: pre-treatment low-density lipoprotein
cholesterol; TG: pre-treatment triglycerides; TotalChol2: total post-treatment
cholesterol; HDL-C2: post-treatment high-density lipoprotein cholesterol; LDL-
C2: post-treatment low-density lipoprotein cholesterol; TG2: post-treatment
triglycerides; CC: homozygous major-allele genotype; CT: heterozygous
genotype; TT: homozygous minor-allele genotype.
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were observed. Moreover, this reduction was primarily
observed in T allele carriers (Table 5). To explore the
hypothesis that the T allele may have influenced the
results, the genotypes were re-classified as either CT or
TT. Although a reduction in lipoprotein was observed,
it was not statistically significant (t = 1.889, p = 0.06).
The significant decrease in triglycerides observed in
the first analysis was seen only in the CT (t = 1.20; p =
0.24) and TT (t = 1.71; p = 0.11) genotypes. A signifi-
cant decrease in triglycerides (t = 3.22; p = 0.02) in T
carriers was also found when the CT and TT genotypes
were grouped together. In contrast, those with the CC
genotype did not show a significant decrease in trigly-
cerides after the treatment (t = 1.07; p = 0.30) [50].
HDL-C and LDL-C did not differ among genotypes
either before or after treatment, even after dividing ana-
lyzing the CT and TT genotypes separately (Table 6).
All of the two-tailed p values associated with these com-
parisons were greater than 0.05. There is speculation
about the relationships between HDL-C metabolism and
HL polymorphisms. However, these polymorphisms
result in only minor variations in HDL-C levels [51],
which is consistent with our findings.
We next examined the influence of the C and T alleles
on the baseline values and on the pre- and post-treatment
conditions. No statistically significant differences in any of
the baseline variables were observed between the patients
with the C allele and those with the T allele (Tables 6 and
7). This finding suggests that the presence of the T allele
(and low hepatic lipase activity) may be associated with a
slightly increased risk of atherosclerosis, despite the high
HDL cholesterol in individuals with the T allele.
The T allele was associated with a significant reduction
in triglycerides. Reduced triglycerides after ERT were
observed in individuals of both the TT and CT geno-
types, but the reduction was more significant in T than C
alleles. These results are indirectly expressed with respect
to genotype; the comparison of the CT and TT patients
showed a trend toward a similar level of triglyceride
reduction (t = 1.889; p = 0.06) (Table 8). These findings
indicate that the mechanism of HRT differs from that of
the typical lipid-lowering drugs; if the mechanism were
the same, the treatment would be expected to have a
greater effect on those with the C allele [7,8,50].
The limitation of our study is the relatively small
number of patients included. However, a strength of our
study is that it is a prospective study of the Brazilian
population, comparing the same women before and
after HRT to address the question of whether or not
lipid levels are associated with the alleles C or T.
Conclusions
In conclusion, HRT seems to reduce triglyceride levels
regardless of the genotype at the C-514T polymorphic
locus. Although individuals with the T allele who receive
HRT appear to have a positive lipid profile, the anti-
atherogenic effect of the T allele is not clear [52,53].
However, the T allele (p-values = 0.93 and 0.02 for cho-
lesterol and triglycerides, respectively) does seem to be a
better genetic marker for total cholesterol and triglycer-
ide levels than the C allele (p values = 0.85 and 0.07 for
cholesterol and triglycerides, respectively). According to
the literature [47], there is large inter-individual variabil-
ity in the plasma lipid response to HT. A similar effect
was not observed for LDL-C or HDL-C.
Methods
Subjects
The study population was derived from a larger study of
hormone replacement therapy in postmenopausal
women. The larger study included a total of 200 patients
from a tertiary outpatient clinic. One hundred of these
women had undergone hysterectomy for myomas and
were receiving HRT consisting of a single daily dose
(0.625 mg) of conjugated equine estrogen The 100 non-
hysterectomized women in the study received hormone
replacement therapy consisting of a daily combination of
0.625 mg estrogen and 2.5 mg of medroxyprogesterone
(estrogen and progestin replacement therapy). Only
those patients who received conjugated equine ERT
exclusively and who presented lipid profiles within the
reference range were enrolled in our study. A total of 58
patients with a mean age of 54 years were selected for
DNA extraction and the subsequent study of the C-514T
HL gene polymorphism both before and after ERT.
The inclusion criteria included the following: 1) a
maximum three-year history of menopause; 2) complete
chart information with annual blood work (complete
blood count with differential, total cholesterol and frac-
tions, triglycerides, urea, creatinine, blood glucose, estra-
diol, progestin, FSH, and LH) that was within the
reference range since the onset of menopause; 3) a bilat-
eral mammogram with BI-RADS classification 1 or 2; 4)
abdominal and pelvic ultrasounds with normal findings;
5) cervical-vaginal cytology that was normal by the
Bethesda classification; and 6) bone densitometry
(patients within one standard deviation of the age-
adjusted mean).
Women who did not comply with the proposed hor-
mone replacement therapy were excluded from the
study, as were those who did not meet the above
criteria.
Information on alcohol use and other lifestyle factors,
such as physical activity and dietary saturated fat, was
not collected. The patients were not instructed to follow
any specific dietary guidelines.
All patients gave free and informed consent to partici-
pate, and the project was approved by the Committee of
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Ethics in Research at the Federal University of São
Paulo, with the number CEP 1114/08
Methods
Buccal tissue samples were obtained with a cytobrush.
Samples were placed in Falcon tubes with Tris-EDTA
buffer and frozen at -80°C for subsequent genomic
DNA extraction. Blood samples were obtained before
and after ERT using a Vacutainer®. The patients were
instructed how to prepare for sampling so as to mini-
mize interference from pre-analytical factors. The
patients were instructed to fast from 10 to 14 hours, to
maintain their usual diet, not to use alcohol within 72
hours prior to the collection and not to perform strenu-
ous exercise on the collection day [54]. Total cholesterol
was measured using the oxidase method. HDL-C was
measured by the direct method and by a homogenous
assay. Triglycerides were measured using an enzymatic
colorimetric method (Advia 1650; Bayer®, USA). The
LDL-C concentration was obtained using Friedwald’s
formula [55]. The intra-assay coefficients of variability
were less than 5%.
DNA of the buccal mucosa was analyzed using a com-
mercially available PCR kit (GFX®; Amersham-Pharma-
cia, USA) according to the manufacturer’s instructions.
PCR was carried out using primers to detect the C-T
change, as described by Somekawa et al. [56]. The fol-
lowing primers were used in this study: LipR, 5’-
TCACTTGGCAAGGGCATCTTTG-3’; and LipF, 5’-
GGTCGGGGTAGGTGGCTTCCA-3’. The PCR proto-
col included 35 cycles at 94°C for 30 s, 55°C for 60 s
and 72°C for 90 s, after 2 min of denaturation at 95°C.
PCR fragments were digested with 1.5 U of NiaIII
restriction enzyme, followed by electrophoresis in a 3%
low-melting agarose gel that was then stained with ethi-
dium bromide. The size of the amplified fragment was
274 bp. Fragments of 226 and 48 bp were obtained for
allele T, and fragments of 274 bp were obtained for
allele C. The genotypes were expressed as CC (major-
allele homozygote (W), 274 bp), CT (heterozygote (H),
274, 226, and 48 bp), and TT (minor-allele homozygote
(M), 226 and 48 bp).
Statistical analysis
Because each individual had more than one set of obser-
vations, we used the paired-samples t-test to compare
the quantitative data; this test is equivalent to a standard
Student’s t-test but is specifically designed for related
samples. It requires that the data have a normal distri-
bution. Thus, we initially used the Kolmogorov-Smirnov
test to verify that the data were normally distributed.
The p value of the non-normality hypothesis was > 0.05
for all of the variables. The results are presented as
mean and standard deviation.
To determine whether genotype influenced the base-
line levels of the variables, we used analysis of variance
(ANOVA). We compared the average values for the
three genotypes in the samples taken before and after
treatment with ERT. The variables included age, total
cholesterol, HDL-C, LDL-C and TGL. Hardy-Weinberg
equilibrium was checked for the entire sample.
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